Company intelligence / Profile preview

ImaRx Therapeutics, Inc.

Tucson, Arizona, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~32
Development stage: Commercial

Overview

The company commercialized urokinase, an FDA-approved thrombolytic agent for treating acute massive pulmonary embolism. Their SonoLysis program (MRX-801 microbubbles with ultrasound and tPA) for ischemic stroke reached Phase 1/2 trials (TUCSON trial), but enrollment was stopped in the second cohort due to safety concerns. The first cohort showed promising safety and efficacy trends.

Therapeutic areas: PsychiatryOncologyCardiovascular
Modalities: Microbubble technologythrombolytics
Industry: Biotech

Drug pipeline

1 asset

perflutren lipid microsphere

Discontinued

Partnerships

Microbix Biosystems

Beyond the preview

Go deeper on ImaRx Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImaRx Therapeutics, Inc..

Explore the full profile